Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Medivolve Inc MEDVF

Medivolve, Inc. is a Canada-based healthcare technology company. The Company has two business units: Medivolve Pharmacy Division (MPD) and Collection Sites Diagnostics (CSD). MPD provides retail pharmacy and mail-order pharmacy services related to COVID-19, antibiotics, dermatology, family medicine, immunology, neurology, pain management, pediatrics, preventive medicine, and psychiatry to... see more

OTCPK:MEDVF - Post Discussion

Medivolve Inc > Here is an idea for the First quarter financials.
View:
Post by Sarb99 on May 10, 2021 8:54pm

Here is an idea for the First quarter financials.

  1. Collection Sites Provides Update With January Sales of 73,973 Tests at an Average Price of $96 per Test. https://stockhouse.com/news/press-releases/2021/02/04/collection-sites-provides-update-with-january-sales-of-73-973-tests-at-an  73,973x$96=$7,101,408
  2. Collection Sites Launches Business to Business Sales Initiatives; Provides Update With February Sales of 30,717 Tests at an Average Price of $98 per Test. https://stockhouse.com/news/press-releases/2021/03/18/correcting-and-replacing-collection-sites-launches-business-to-business-sales 30,717x$98=$3,010,266
  3. Medivolve Subsidiary Collection Sites Provides March Sales Update With Total Sales of 20,574 Tests at an Average Price of $99 per Test. https://stockhouse.com/news/press-releases/2021/04/06/medivolve-subsidiary-collection-sites-provides-march-sales-update-with-total 20,574x$99=$2,036,826

Now here is the total for January, February and March.

 

  1. All amounts are in USD and need to be converted $7,101,408+$3,010,266+$2,036,826

Total amount USD 12,148,500 Converting to Canadian

12,148,500x1.25=$15,185,625 

 

This amount can change little with different conversion rates or a few extra small contracts. 

Comment by Chrisvaughan on May 10, 2021 9:04pm
Great revenue from a single source
Comment by Chrisvaughan on May 10, 2021 9:14pm
With that kinda revenue the market cap is so skewed. Also should have Nuturelle revenues in future and on top all this blowfish. You would think the csp should be 20x what it is now
Comment by StopProfit on May 11, 2021 4:06am
Still trading at <.20. It is a shame!
Comment by Frosted on May 10, 2021 11:18pm
Based on those numbers which seem pretty accurate, what do you think the share precie should be?
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities